Form 4: Guardant Health Director Sells Shares Under 10b5-1 Plan

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), reported a sale of common stock.
• The transaction involved the disposition of 26 shares of common stock.
• The shares were sold at a price of $59.02 per share.
• The transaction occurred on August 19, 2025.
• The sale was conducted pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction.
• Following this transaction, Ms. Potter beneficially owns 18,239 shares of Guardant Health common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's a director selling shares, the quantity is very small (26 shares out of 18,239 remaining), and it was conducted under a pre-arranged 10b5-1 plan, which mitigates any negative signal typically associated with insider sales.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which indicates a pre-scheduled sale and not a discretionary sale based on new, non-public information, potentially reducing concerns about insider sentiment.

Negatives

• A director's sale of shares, even a small amount, can sometimes be perceived as a slight negative signal, though mitigated by the 10b5-1 plan.

Risks

• No specific risks beyond the inherent market risks associated with stock ownership are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is specific to Guardant Health and does not directly reflect broader industry trends. However, insider trading activity is a common data point for analysts assessing company-specific sentiment within the biotechnology and healthcare sectors.

Comparison to Industry Standards

• The sale of 26 shares is a very small transaction relative to the director's total holdings (18,239 shares remaining), suggesting it is likely for personal liquidity or tax planning rather than a significant change in investment thesis.
• The use of a Rule 10b5-1 plan is a standard practice for corporate insiders to manage stock sales in compliance with insider trading regulations, aligning with best practices in corporate governance.

Corporate Governance

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal due to the small number of shares sold. The 10b5-1 plan provides transparency regarding the nature of the sale.

Key Dates

Keywords

Guardant Health, GH, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Stock Transaction, Biotechnology, Healthcare